GSK (GSK.US)日前宣布，美国FDA已授予其PD-1抑制剂Jemperli (dostarlimab)用于治疗局部晚期错配修复缺陷 (dMMR)/高微卫星不稳定性 (MSI-H)直肠癌的突破性疗法认定 (BTD)。 这是dostarlimab在局部晚期dMMR/MSI-H直肠癌适应症上获得的第二项监管认定，该疗法在2023年1月曾获FDA授予快速通道资格。

GSK PLC GSK shares inched down 0.90% to £13.22 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 1.14% to 8,105.32.

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

GSK PLC GSK shares rose 1.06% to £13.34 Tuesday, on what proved to be an all-around dismal trading session for the stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms ...

Analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of GSK in a research note issued to investors on ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the ...